All PlansPrior AuthMedium impact
Low-Level Laser Therapy
Regence BlueShield·Oncology, Radiation Oncology·Prior Authorization
Effective date
Oct 1, 2026
We identified it
Jul 7, 2026
Summary
This new policy establishes coverage criteria for low-level laser therapy (photobiomodulation), effective October 1, 2026. Coverage is limited to FDA-approved devices used for prevention of oral mucositis in cancer patients undergoing chemotherapy, radiotherapy, and/or hematopoietic cell transplantation. All other uses are classified as investigational and not covered. Prior authorization with specific clinical documentation is required.
Action Required
Before October 1, 2026: Billing team must implement prior authorization workflow for low-level laser therapy claims. (1) Update billing system to route all LLLT claims to prior authorization queue. (2) Create prior authorization template requiring submission of: History and Physical/Chart Notes, current symptomology and indication, manufacturer and model name of device, and documentation that patient has cancer with high risk of oral mucositis from treatment (chemotherapy, radiotherapy, and/or hematopoietic cell transplantation). (3) Providers must document that device is FDA-approved before billing. (4) Providers and front desk staff must inform patients that LLLT for any indication other than oral mucositis prevention in cancer patients is investigational and the patient will be financially responsible for costs. (5) Training: Educate billing team, providers, and clinical staff on coverage criteria. Failure to obtain prior authorization or submit required documentation will result in claim denials. Claims for non-covered indications (carpal tunnel syndrome, Bell's palsy, tendinopathy, musculoskeletal disorders, etc.) will be denied.